2021 Year in Review - Multiple Myeloma
Longer follow-up results of the phase 2 GRIFFIN trial demonstrated that the addition of daratumumab to RVd induction/consolidation in conjunction with ASCT, followed by 24 months of daratumumab-lenalidomide maintenance resulted in deep and durable responses, including stringent CR and MRD negativity rates, in patients with transplant-eligible NDMM.
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd), Autologous Transplantation, and MRD Response–Adapted Treatment Modification in NDMM
These results indicate that quadruplet induction therapy with daratumumab plus carfilzomib, lenalidomide, and dexamethasone (D-KRd); ASCT; and MRD response–adapted D-KRd consolidation therapy yielded high MRD negativity rates in patients with NDMM.
Longer-Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with RRMM: 13-Month Follow-Up from the Pivotal DREAMM-2 Study
Longer-term data from the DREAMM-2 trial confirmed the sustained clinical activity of the anti–B-cell maturation antigen antibody–drug conjugate belantamab mafodotin in heavily pretreated patients with RRMM, with no emergence of new safety signals.
Results of the Phase 3 GMMG-HD7 Trial of Isatuximab plus Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Transplant-Eligible NDMM
Initial primary analysis results of the ongoing phase 3 GMMG-HD7 trial demonstrated that the addition of isatuximab to the standard-of-care RVd regimen was associated with superior MRD negativity rates after induction, and the regimen was not accompanied by emergence of new safety signals or early discontinuation.
Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy
In the CARTITUDE-2 cohort A that included patients with MM who had received 1 to 3 previous lines of therapy and were lenalidomide-refractory, a single infusion of cilta-cel CAR T-cell therapy produced early and deep responses, with a manageable safety profile.
MAIA Trial Results of Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in NDMM
Interim analysis results of the phase 3 MAIA trial demonstrated that frontline daratumumab plus lenalidomide/dexamethasone provided OS benefit compared with lenalidomide/dexamethasone in patients with NDMM ineligible for stem-cell transplantation.
CARDAMON Trial Results of Carfilzomib Maintenance Following Transplantation or Carfilzomib/Cyclophosphamide/Dexamethasone Consolidation for NDMM
Results of the CARDAMON trial indicate that, although carfilzomib maintenance was feasible and yielded higher MRD negativity rates at 6 months with ASCT than with consolidation, it was associated with a higher incidence of grade ≥3 adverse events and discontinuations after ASCT.
Page 1 of 3
Results 1 - 10 of 26
Results 1 - 10 of 26